Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGiaccone, G.en
dc.contributor.authorSmit, E. F.en
dc.contributor.authorde Jonge, M.en
dc.contributor.authorDansin, E.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorArdizzoni, A.en
dc.contributor.authorDouillard, J. Y.en
dc.contributor.authorSpaeth, D.en
dc.contributor.authorLacombe, D.en
dc.contributor.authorBaron, B.en
dc.contributor.authorBachmann, P.en
dc.contributor.authorFumoleau, P.en
dc.rightsDefault Licence-
dc.subjectAntineoplastic Agents/*administration & dosage/adverse effects/pharmacokineticsen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapyen
dc.subjectChild, Preschoolen
dc.subjectDisease Progressionen
dc.subjectDrug Administration Scheduleen
dc.subjectGlucose/analogs & derivativesen
dc.subjectIfosfamide/analogs & derivativesen
dc.subjectInfusions, Intravenousen
dc.subjectLung Neoplasms/*drug therapyen
dc.subjectMiddle Ageden
dc.subjectPhosphoramide Mustards/*administration & dosage/adverse effects/pharmacokineticsen
dc.subjectProspective Studiesen
dc.titleGlufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Groupen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractThe activity of glufosfamide (beta-D-glucosylisophosphoramide mustard) was tested in a multicentre phase II clinical trial in patients with advanced non-small cell lung cancer (NSCLC) who had received one prior line of platinum-based chemotherapy. Patients were treated with 5000 mg/m(2) glufosfamide by a 1-h intravenous (i.v.) infusion every 3 weeks following registration at the European Organisation for Research and Treatment of Cancer (EORTC) Data Center. Patients were randomised between hydration and no hydration to evaluate the nephroprotective effects of forced diuresis. Patients experiencing >/= 35 micromol/l increase of serum creatinine compared with baseline values were taken off the treatment. The Response evaluation criteria in solid tumours (RECIST) criteria were applied for the response assessment. Blood sampling was performed for a pharmacokinetic analysis. 39 patients from seven institutions were registered and a median of three cycles was given (range 0-6) cycles; 20 patients were randomised to the hydration arm. Haematological toxicity was mild, but treatment-related metabolic and electrolytic abnormalities and increases of serum creatinine occurred in several patients. Hydration did not have any significant influence on the plasma pharmacokinetics of glufosfamide and did not show any nephroprotective effect. Only one confirmed partial remission was observed (response rate 3%; 95% (Confidence Interval (CI) 0-14) and 18 cases with stable disease (49%) were recorded as assessed by an independent panel. Median survival of all patients treated was 5.8 months (95% CI 4.2-7.9). In conclusion, glufosfamide administered by a 1-h infusion every 3 weeks has modest activity in advanced NSCLC patients after one prior platinum-based chemotherapy.en
heal.journalNameEur J Canceren
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Giaccone-2004-Glufosfamide adminis.pdf169.83 kBAdobe PDFView/Open    Request a copy

This item is licensed under a Creative Commons License Creative Commons